Broderick Brian C Has $15.54 Million Stake in Danaher Co. (NYSE:DHR)

Broderick Brian C grew its holdings in shares of Danaher Co. (NYSE:DHR) by 4.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,224 shares of the conglomerate’s stock after acquiring an additional 2,633 shares during the quarter. Danaher comprises 3.3% of Broderick Brian C’s investment portfolio, making the stock its 10th largest position. Broderick Brian C’s holdings in Danaher were worth $15,539,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Cape Investment Advisory Inc. purchased a new position in shares of Danaher during the 4th quarter valued at about $25,000. Tsfg LLC raised its holdings in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. BKM Wealth Management LLC purchased a new position in shares of Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher during the 4th quarter valued at about $29,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Danaher during the 1st quarter valued at about $30,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the topic of a number of analyst reports. TD Cowen lifted their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Danaher Stock Up 1.7 %

Danaher stock traded up $4.07 during mid-day trading on Thursday, hitting $246.27. The company had a trading volume of 2,793,164 shares, compared to its average volume of 2,861,634. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock’s 50 day moving average price is $255.05 and its two-hundred day moving average price is $247.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The company has a market capitalization of $182.41 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 3.68 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the company posted $2.36 earnings per share. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock worth $37,536,717 over the last quarter. 10.90% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.